Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Data from a retrospective study of 330 patients with metastatic NSCLC treated with immune checkpoint inhibitors (ICIs) showed that presence of bone metastases at baseline was associated with a worse prognosis. The 124 patients in the study who had baseline bone metastasis had a higher hazard of death after controlling for performance status, histology, line of therapy, and disease burden (hazard ratio, 1.57; 95% CI, 1.19–2.08; P=.001).